ALC News and Press, Alcon Inc. From 05/06/23

An investigator led, non-interventional study evaluated the performance of two monofocal intraocular lenses (IOLs) in 620 eyes of 310 cataract patients in the U.S. 1 Clareon monofocal IOL provides excellent distance vision, and intermediate vision that is non-inferior to TECNIS Eyhanc...

Alcon innovations featured in approximately 180 abstracts across cataract, glaucoma, refractive, visualization and ocular health 1 New data demonstrates comparable range of vision and intermediate visual acuity between Clareon monofocal IOL and TECNIS Eyhance* monofocal IOL 2 ...

Alcon welcomes its shareholders to its first in-person AGM In addition to the regular agenda items, Alcon Board of Directors proposes to amend the Articles of Incorporation to conform to recent Swiss corporate law reform Proposed dividend of CHF 0.21 cash per share ...

Silver Anthem Award Recognizes The Lens as Best Special Workforce Initiative: Health Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that its interactive compliance training video experience, The Lens, has been named Best Special Workf...

Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2023 Capital Markets Day on March 30, 2023 beginning at 8:00 a.m. CT. A live webcast of the event will be available at https://investor.alcon.com/news-and-events/events-and-presentations/default.aspx . About Alcon...

TOTAL30 for Astigmatism, the first and only reusable Water Gradient toric lens, is now available nationwide in the U.S. Alcon highlights the expansion of its toric lens portfolio with latest innovations, including DAILIES TOTAL1 for Astigmatism and PRECISION1 for Astigmatism, to be showcased ...

Alcon Inc. (ALC) Q4 2022 Earnings Conference Call February 28, 2023 08:00 ET Company Participants Dan Cravens - Vice President & Global Head of Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Cal...

Summary Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie. Brent Saunders likely signed on as CEO with the expectation of operating Bausch + Lomb Corporation as a fully standalone company. ...

Alcon press release ( NYSE: ALC ): Q4 Non-GAAP EPS of $0.42 in-line. Revenue of $2.16B (+1.4% Y/Y) in-line. Surgical net sales, which include implantables, consumables and equipment/other, were $1.3 billion, an increase of 1% on a reported basis Implantables net sales of $...

Fourth quarter 2022 sales of $2.2 billion, up 1%, or 7% constant currency (1) (cc) Full year 2022 sales of $8.7 billion, up 5%, or up 11% cc Full year 2022 diluted EPS of $0.68, down 11%, or up 37% cc; core diluted EPS (2) of $2.24 up 4%, or 23% cc 2023 outlook ref...